Who Generates Higher Gross Profit? Eli Lilly and Company or Dr. Reddy's Laboratories Limited

Eli Lilly vs. Dr. Reddy's: A Decade of Gross Profit Trends

__timestamp	Dr. Reddy's Laboratories Limited	Eli Lilly and Company
Wednesday, January 1, 2014	75801000000	14683100000
Thursday, January 1, 2015	85403000000	14921500000
Friday, January 1, 2016	92281000000	15567200000
Sunday, January 1, 2017	78356000000	16801100000
Monday, January 1, 2018	76304000000	16811600000
Tuesday, January 1, 2019	83430000000	17598300000
Wednesday, January 1, 2020	94009000000	19056500000
Friday, January 1, 2021	103077000000	21005600000
Saturday, January 1, 2022	113840000000	21911600000
Sunday, January 1, 2023	202972000000	27041900000
Monday, January 1, 2024	163607000000	36624400001

Data in motion

A Tale of Two Giants: Eli Lilly vs. Dr. Reddy's Laboratories

In the competitive world of pharmaceuticals, gross profit is a key indicator of a company's financial health and market dominance. Over the past decade, Dr. Reddy's Laboratories Limited has consistently outperformed Eli Lilly and Company in terms of gross profit. From 2014 to 2023, Dr. Reddy's gross profit surged by approximately 167%, peaking in 2023. In contrast, Eli Lilly's growth was more modest, with a 84% increase over the same period.

While Eli Lilly's gross profit reached its highest in 2023, it still lagged behind Dr. Reddy's by a significant margin. This disparity highlights the strategic differences and market positioning of these two pharmaceutical powerhouses. As we look to the future, the absence of data for 2024 for Eli Lilly leaves room for speculation on whether it can close the gap.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025